DoctorCorinne Mirkazemi

(She/her)

Senior Lecturer in Pharmacy Practice

Pharmacy

  • Senior Lecturer in Pharmacy Practice
    Pharmacy
  • +61 3 6226 1083 (Work)
  • +61 3 6226 7627 (Fax)
  • School of Pharmacy and Pharmacology, Pharmacy, Pharmacy Building, Sandy Bay Campus, TAS

RESEARCH SUMMARy

Dr Mirkazemi's research aligns with the University's Better Health theme. Her research interests broadly relate to preventative and primary healthcare. She is currently working on projects relating to the below areas of expertise, and welcomes opportunities for collaboration.

  • Thromboprophylaxis
  • Vitamin B12 deficiency
  • Iodine deficiency disorders
  • Breastfeeding
  • Nutrition in Pharmacy Practice
  • Gut microbiome
  • Maternal health
  • Pharmacy services (e.g. Diabetes Medschecks)
  • Budget Impact Analyses
  • Anticoagulation and AF
  • Cancer and Cardiovascular disease

 

Corinne also serves as Graduate Research Coordinator and Coordinator of the Bachelor of Pharmacy Honours (54B) degree and associated research units. She is also currently supervising five PhD candidates, having supervised two PhD to completion (2019, 2024). She has also supervised seven Masters and six Honours students to completion in recent years.

FUNDED PROJECTS

  • GRANT
    Does the improved atrial fibrillation management during hospitalisation persist and improve clinical outcomes?
    1 Aug 2026 - 31 Jan 2028
    People funded by this grant:
    • Gelaw B,
    • Bezabhe W,
    • Dwyer N,
    • Peterson G,
    • Mirkazemi C
    Project Total: $7,000; Atrial fibrillation (AF) affects nearly 500,000 Australians, with prevalence expected to double within two decades due to population ageing, improved survival from AF-associated risk factors, and enhanced detection. AF increases the risk of ischaemic stroke fivefold, and approximately one-third of all strokes are attributable to AF. These events are disproportionately severemore likely to be fatal, recurrent, and economically burdensomecosting the Australian healthcare system an estimated $5 billion annually. Oral anticoagulants (OACs) reduce stroke risk by 64%, yet real-world persistence remains suboptimal. Our recent study at the Royal Hobart Hospital (RHH), published in the European Journal of Clinical Investigation and supported by the 2023 Royal Hobart Research Foundation (RHHRF) Incubator Grant, demonstrated that multidisciplinary care improved guideline-concordant OAC prescribing from 53.8% at admission to 73.8% at discharge. The studys clinical relevance was further underscored in an invited editorial by Boriani et al, a member of the European Society of Cardiology Guidelines Committee. Despite gains in initiation, continuity of OAC therapy post-discharge, incidence of cardiovascular-related rehospitalisation and stroke, and the implementation of integrated AF management remain unexamined in Tasmania and nationally. This study will generate real-world evidence across the following areas: (i) rates and factors of OAC discontinuation at 12 months; (ii) incidence and drivers of cardiovascular-related rehospitalisation and stroke; and (iii) adherence to the ABC pathway (Avoid stroke, Better symptom control, Cardiovascular/comorbidity management) and its impact on clinical outcomes. By addressing these gaps, the study directly supports Australias national health priority of cardiovascular disease by targeting AF and its common comorbidities. These efforts align with national strategies to reduce stroke risk and improve chronic disease management across high-burden populations. Given that OACs are among the most clinically impactful yet high-risk therapies, enhancing their safe and sustained use is a national imperative. Findings will strengthen evidence-based practice, empower multidisciplinary teams, and promote holistic AF care that extends beyond stroke preventionultimately improving patient outcomes in Tasmania and across Australia. Funded by: Royal Hobart Hospital Research Foundation - Research Project Grant ($7,000); University of Tasmania.
  • GRANT
    Optimising Oral Anticoagulant Use in Hospitlised Patients with Atrial Fibrillation: An Opportunity Enhancement Intervention.
    1 Jan 2025 - 30 Dec 2026
    People funded by this grant:
    • Bezabhe W,
    • Peterson G,
    • Dwyer N,
    • Mirkazemi C,
    • Black DA
    Project Total: $25,000; Appropriate use of oral anticoagulants (OACs) reduces the risk of stroke and death by 64% and 25%, respectively. In our previous study that compared OAC prescribing at admission (community) and discharge (hospital), we confirmed that, in routine care, the RHH team improved the guideline appropriateness of OAC use in patients with atrial fibrillation. However, half of the patients with guideline-inappropriate OAC prescribing at admission were discharged without correction. The efficiency of correcting inappropriate OAC use varied significantly across RHH admission wards. An intervention that enhances the likelihood of the RHH care team to correct inappropriate OAC use is required. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($25,000); University of Tasmania.
  • GRANT
    Use of Cardiovascular Disease Preventive Medications in Tasmanian Cancer Survivors
    1 Jan 2025 - 31 Dec 2025
    People funded by this grant:
    • Bezabhe W,
    • Peterson G,
    • Black DA,
    • Mirkazemi C,
    • Dwyer N
    Project Total: $10,000; The number of Tasmanians living with cancer is estimated to be over 30,000 and is increasing. A study using the Tasmanian Cancer Registry data found that heart and blood vessel disorders known as cardiovascular disease (CVD) are the leading causes of non-cancer death in Tasmanians with cancer. Over a quarter of all deaths and more than half of all non-cancer deaths are caused by CVD. However, no study examined the use of CVD preventive medications in Tasmanian cancer survivors. This study aims to investigate CVD preventive medication use following acute coronary syndrome admission in Tasmanian cancer survivors. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($10,000); University of Tasmania.
  • GRANT
    Blood clots in Tasmanian cancer patients: what is the risk and how effectively are we preventing them?
    1 Jan 2021 - 31 Dec 2021
    People funded by this grant:
    • Batt T,
    • Mirkazemi C,
    • Peterson G,
    • Bereznicki L
    Project Total: $9,497; Blood clots are a serious and often life-threatening complication of cancer that can be largely avoided with appropriate care. We will review preventative practices used locally, as well as associated influences, with the aim to optimise care and reduce this risk in future Tasmanians diagnosed with cancer. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator; University of Tasmania.
  • GRANT
    Field testing the reliability and cost-effectiveness of a novel locally developed assay for determining urine iodine concentration in urine samples
    1 Jan 2021 - 31 Dec 2022
    People funded by this grant:
    • Mirkazemi C,
    • Hynes K,
    • Patel R,
    • Nichols D,
    • Seal J
    Project Total: $8,420; Tasmania's long history of iodine deficiency has improved, but some groups and individuals remain at-risk of adverse consequences, including brain-damage. Research is impeded by the high cost of current iodine status assays (due to having to send them interstate). This project will enhance research capacity by demonstrating the reliability of a novel, locally developed low-cost method. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($8,420); University of Tasmania.
  • GRANT
    A fresh look at local practice to prevent blood clots following hip and knee replacement surgery
    1 Jan 2019 - 31 Dec 2019
    People funded by this grant:
    • Mirkazemi C,
    • Peterson G,
    • Bereznicki L,
    • Batt T
    Project Total: $9,791; The project is a retrospective audit of thromboprophylaxis prescribing for hip and knee arthroplasty patients who have undergone (or will undergo) surgery at the RHH between June 2017 and June 2019. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($9,791); University of Tasmania.
  • GRANT
    Collaboration to build laboratory capacity within Tasmania for measurement of iodine in biological samples
    1 Jan 2018 - 31 Dec 2018
    People funded by this grant:
    • Hynes K,
    • Mirkazemi C,
    • Patel R,
    • Oddy W,
    • Nichols D
    Project Total: $9,800; Tasmania does not currently have accredited laboratory facilities to determine iodine concentration of biological samples collected in Tasmanian research studies and monitoring projects. Sending samples interstate or overseas is becoming prohibitively expensive. This collaboration will facilitate establishment of cost-effective laboratory capacity in Tasmania. The proposed project will test and validate three types of assays for determination of iodine concentration in a range of biological samples routinely collected in Tasmanian research projects. Funded by: University of Tasmania - Grant- Research Enhancement Program; University of Tasmania ($9,800).
  • GRANT
    Evidence to Practice Gap: Factors that Influence Practices to Prevent Blood Clots Following Hip and Knee Replacement Surgery
    11 Apr 2011 - 11 Apr 2012
    People funded by this grant:
    • Peterson G,
    • Bereznicki L,
    • Hansen E,
    • Mirkazemi C
    Project Total: $4,545; Funded by: Royal Hobart Hospital Research Foundation - Grant-Starter ($4,545); University of Tasmania.